Finerenone for treating chronic kidney disease in type 2 diabetes | TA877 | | |
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer | TA876 | | |
Eptinezumab for preventing migraine | TA871 | | |
Cannabidiol for treating seizures caused by tuberous sclerosis complex | TA873 | | |
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma | TA874 | | |
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies | TA872 | | |
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | TA870 | | |
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) | TA867 | | |
Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) | TA869 | | |
Vutrisiran for treating hereditary transthyretin-related amyloidosis | TA868 | | |
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma | TA865 | | |
Regorafenib for previously treated metastatic colorectal cancer | TA866 | | |
Upadacitinib for treating active non-radiographic axial spondyloarthritis | TA861 | | |
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 | | |
Somatrogon for treating growth disturbance in children and young people aged 3 years and over | TA863 | | |
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted | TA864 | | |
Maribavir for treating refractory cytomegalovirus infection after transplant | TA860 | | |
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) | TA859 | | |
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma | TA857 | | |
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma | TA858 | | |
Upadacitinib for treating moderately to severely active ulcerative colitis | TA856 | | |
Avatrombopag for treating primary chronic immune thrombocytopenia | TA853 | | |
Cabozantinib for previously treated advanced hepatocellular carcinoma | TA849 | | |
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy | TA850 | | |
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | TA851 | | |
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments | TA852 | | |
Esketamine nasal spray for treatment-resistant depression | TA854 | | |
Memokath 051 Ureter stent for ureteric obstruction | MTG75 | | |
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) | TA848 | | |
Optilume for treating recurrent bulbar urethral strictures | MTG73 | | |
GreenLight XPS for treating benign prostatic hyperplasia | MTG74 | | |
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) | TA845 | | |
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) | TA846 | | |
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA847 | | |
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) | TA844 | | |
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) | TA843 | | |
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA841 | | |
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) | TA842 | | |
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) | TA839 | | |
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids
(terminated appraisal) | TA840 | | |
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) | TA838 | | |
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | TA837 | | |
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA836 | | |
Pembrolizumab for adjuvant treatment of renal cell carcinoma | TA830 | | |
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids | TA832 | | |
Zanubrutinib for treating Waldenstrom's macroglobulinaemia | TA833 | | |
Fostamatinib for treating refractory chronic immune thrombocytopenia | TA835 | | |
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) | TA834 | | |
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer | MTG72 | | |
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy | TA827 | | |
Ozanimod for treating moderately to severely active ulcerative colitis | TA828 | | |
Upadacitinib for treating active ankylosing spondylitis | TA829 | | |
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA823 | | |
Neuropad for detecting preclinical diabetic peripheral neuropathy | MTG38 | | |
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis | TA825 | | |
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) | TA826 | | |
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) | TA822 | | |
Dexamethasone intravitreal implant for treating diabetic macular oedema | TA824 | | |
Faecal microbiota transplant for recurrent Clostridioides difficile infection | MTG71 | | |
Brolucizumab for treating diabetic macular oedema | TA820 | | |
iFuse for treating chronic sacroiliac joint pain | MTG39 | | |
Avalglucosidase alfa for treating Pompe disease | TA821 | | |
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies | TA819 | | |
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | TA818 | | |
SecurAcath for securing percutaneous catheters | MTG34 | | |
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA815 | | |
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | | |
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence | TA817 | | |
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer | TA812 | | |
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors | TA813 | | |
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis | TA814 | | |
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) | TA811 | | |
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease | TA809 | | |
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | | |
PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites | MTG9 | | |
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA803 | | |
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides | TA805 | | |
Belimumab for treating lupus nephritis (terminated appraisal) | TA806 | | |
Roxadustat for treating symptomatic anaemia in chronic kidney disease | TA807 | | |
Fenfluramine for treating seizures associated with Dravet syndrome | TA808 | | |
MiraQ for assessing graft flow during coronary artery bypass graft surgery | MTG8 | | |
Teduglutide for treating short bowel syndrome | TA804 | | |
Faricimab for treating diabetic macular oedema | TA799 | | |
Faricimab for treating wet age-related macular degeneration | TA800 | | |
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | TA801 | | |
Cemiplimab for treating advanced cutaneous squamous cell carcinoma | TA802 | | |
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation | TA798 | | |
Venetoclax for treating chronic lymphocytic leukaemia | TA796 | | |
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 | | |
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) | TA793 | | |
Diroximel fumarate for treating relapsing–remitting multiple sclerosis | TA794 | | |
Ibrutinib for treating Waldenstrom's macroglobulinaemia | TA795 | | |
Peristeen Plus transanal irrigation system for managing bowel dysfunction | MTG36 | | |
Thopaz+ portable digital system for managing chest drains | MTG37 | | |
Filgotinib for treating moderately to severely active ulcerative colitis | TA792 | | |
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) | TA790 | | |
Romosozumab for treating severe osteoporosis | TA791 | | |
Sleepio to treat insomnia and insomnia symptoms | MTG70 | | |
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations | TA789 | | |
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy | TA788 | | |
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies | TA786 | | |
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA787 | | |
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | TA784 | | |
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) | TA785 | | |
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma | TA783 | | |
myCOPD for managing chronic obstructive pulmonary disease | MTG68 | | |
UroShield for preventing catheter-associated urinary tract infections | MTG69 | | |
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer | TA781 | | |
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) | TA782 | | |
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma | TA780 | | |
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA779 | | |
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA774 | | |
Empagliflozin for treating chronic heart failure with reduced ejection fraction | TA773 | | |
Dapagliflozin for treating chronic kidney disease | TA775 | | |
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA776 | | |
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA777 | | |
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria | TA778 | | |
Prontosan for treating acute and chronic wounds | MTG67 | | |
3C Patch for treating diabetic foot ulcers | MTG66 | | |
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies | TA772 | | |
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer | TA770 | | |
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) | TA771 | | |
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) | TA762 | | |
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable | TA763 | | |
Fremanezumab for preventing migraine | TA764 | | |
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA765 | | |
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma | TA766 | | |
Ponesimod for treating relapsing–remitting multiple sclerosis | TA767 | | |
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA768 | | |
Palforzia for treating peanut allergy in children and young people | TA769 | | |
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care | MTG65 | | |
Sodium zirconium cyclosilicate for treating hyperkalaemia | TA599 | | |
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA761 | | |
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA760 | | |
Cabotegravir with rilpivirine for treating HIV-1 | TA757 | | |
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy | TA758 | | |
Endo-SPONGE for treating low rectal anastomotic leak | MTG63 | | |
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA756 | | |
Belimumab for treating active autoantibody-positive systemic lupus erythematosus | TA752 | | |
Cenobamate for treating focal onset seizures in epilepsy | TA753 | | |
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome | TA754 | | |
ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections | MTG62 | | |
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) | TA750 | | |
Dupilumab for treating severe asthma with type 2 inflammation | TA751 | | |
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders | TA748 | | |
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) | TA749 | | |
Synergo for non-muscle-invasive bladder cancer | MTG61 | | |
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer | TA746 | | |
Nintedanib for treating progressive fibrosing interstitial lung diseases | TA747 | | |
Upadacitinib for treating moderate rheumatoid arthritis | TA744 | | |
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) | TA745 | | |
Selpercatinib for treating advanced thyroid cancer with RET alterations | TA742 | | |
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | TA740 | | |
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA741 | | |
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable | TA739 | | |
Tofacitinib for treating juvenile idiopathic arthritis | TA735 | | |
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy | TA736 | | |
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer | TA737 | | |
Berotralstat for preventing recurrent attacks of hereditary angioedema | TA738 | | |
Secukinumab for treating moderate to severe plaque psoriasis in children and young people | TA734 | | |
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) | TA732 | | |
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA733 | | |
DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography | MTG60 | | |
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) | TA730 | | |
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) | TA731 | | |
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA726 | | |
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA727 | | |
Midostaurin for treating advanced systemic mastocytosis | TA728 | | |
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria | TA729 | | |
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | | |
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer | TA724 | | |
Bimekizumab for treating moderate to severe plaque psoriasis | TA723 | | |
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA722 | | |
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome | TA139 | | |
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | TA720 | | |
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | | |
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA716 | | |
ENDURALIFE powered CRT-D devices for treating heart failure | MTG33 | | |
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) | TA717 | | |
Ixekizumab for treating axial spondyloarthritis | TA718 | | |
Secukinumab for treating non-radiographic axial spondyloarthritis | TA719 | | |
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA714 | | |
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | | |
Enzalutamide for treating hormone-sensitive metastatic prostate cancer | TA712 | | |
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy | TA713 | | |
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA275 | | |
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation | TA249 | | |
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation | TA256 | | |
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA355 | | |
Plus Sutures for preventing surgical site infection | MTG59 | | |
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis | TA708 | | |
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA709 | | |
Ravulizumab for treating atypical haemolytic uraemic syndrome | TA710 | | |
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer | TA707 | | |
Ozanimod for treating relapsing–remitting multiple sclerosis | TA706 | | |
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer | TA705 | | |
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) | TA702 | | |
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) | TA703 | | |
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | TA704 | | |
HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography | MTG32 | | |
Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers | MTG20 | | |
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria | TA698 | | |
Ofatumumab for treating relapsing multiple sclerosis | TA699 | | |
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) | TA701 | | |
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy | TA696 | | |
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban | TA697 | | |
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia | MTG58 | | |
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA692 | | |
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA694 | | |
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma | TA695 | | |
Avelumab for treating metastatic Merkel cell carcinoma | TA517 | | |
Acalabrutinib for treating chronic lymphocytic leukaemia | TA689 | | |
Avelumab for untreated metastatic Merkel cell carcinoma | TA691 | | |